PMID- 12433679
OWN - NLM
STAT- MEDLINE
DCOM- 20030407
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 101
IP  - 6
DP  - 2003 Mar 15
TI  - A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks 
      FGFR3 expression but maintains an IGH/MMSET fusion transcript.
PG  - 2374-6
AB  - Previous studies have revealed that that approximately 10% to 15% of multiple 
      myelomas (MMs) are characterized by a reciprocal t(4;14)(p16;q32) translocation 
      that activates expression of FGFR3 and creates an IGH/MMSET fusion transcript. 
      Current data suggest that activation of FGFR3 is the oncogenic consequence of 
      this rearrangement. Using a combination of microarray profiling, reverse 
      transcriptase-polymerase chain reaction (RT-PCR), and interphase fluorescence in 
      situ hybridization (FISH), we show that 32 (18%) of 178 newly diagnosed cases of 
      MM harbor the t(4;14)(p16;q32). Importantly, 32% of these cases lack expression 
      of FGFR3, yet express MMSET and have an IGH/MMSET fusion transcript. Interphase 
      FISH showed that whereas the IGH/MMSET fusion was present in more than 80% of the 
      clonotypic plasma cells in these novel cases, there was typically a complete loss 
      of one copy of FGFR3. These data indicate that the t(4;14)(p16;q32) and loss of 
      FGFR3 occurred at a very early stage and suggest that activation of MMSET, not 
      FGFR3, may be the critical transforming event of this recurrent translocation.
FAU - Santra, Madhumita
AU  - Santra M
AD  - Donna and Donald Lambert Laboratory of Myeloma Genetics at the Myeloma Institute 
      for Research and Therapy, University of Arkansas for Medical Sciences, Little 
      Rock, AR 72205, USA.
FAU - Zhan, Fenghuang
AU  - Zhan F
FAU - Tian, Erming
AU  - Tian E
FAU - Barlogie, Bart
AU  - Barlogie B
FAU - Shaughnessy, John Jr
AU  - Shaughnessy J Jr
LA  - eng
GR  - CA55819/CA/NCI NIH HHS/United States
GR  - CA97513/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20021114
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (IgH-MMSET fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Fibroblast Growth Factor)
RN  - EC 2.7.10.1 (FGFR3 protein, human)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3)
SB  - IM
MH  - Bone Marrow/chemistry
MH  - *Chromosomes, Human, Pair 14
MH  - *Chromosomes, Human, Pair 4
MH  - Gene Expression
MH  - Gene Expression Profiling
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Multiple Myeloma/*genetics
MH  - Oligonucleotide Array Sequence Analysis
MH  - Oncogene Proteins, Fusion/*genetics
MH  - *Protein-Tyrosine Kinases
MH  - RNA, Messenger/analysis
MH  - Receptor, Fibroblast Growth Factor, Type 3
MH  - Receptors, Fibroblast Growth Factor/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - *Translocation, Genetic
EDAT- 2002/11/16 04:00
MHDA- 2003/04/08 05:00
CRDT- 2002/11/16 04:00
PHST- 2002/11/16 04:00 [pubmed]
PHST- 2003/04/08 05:00 [medline]
PHST- 2002/11/16 04:00 [entrez]
AID - S0006-4971(20)57359-X [pii]
AID - 10.1182/blood-2002-09-2801 [doi]
PST - ppublish
SO  - Blood. 2003 Mar 15;101(6):2374-6. doi: 10.1182/blood-2002-09-2801. Epub 2002 Nov 
      14.